Astellas Launches Irritable Bowel Syndrome Drug Irribow
This article was originally published in PharmAsia News
Executive Summary
Astellas launched Irribow (ramosetron) Oct. 7 in Japan, a drug indicated to treat diarrhea-predominant irritable bowel syndrome in males. A serotonin 5-HT3 receptor antagonist, Irribow is the first serotonin receptor antagonist treatment in Japan. (Click here for more - Japanese language